The course will provide a comprehensive update on the treatment of thoracic malignancies with special emphasis on the multimodality treatment. To that regard there is a wide participation of thoracic surgeons, chest physicians and oncologists.
At the end of the course participants will be able to:
– have a deeper knowledge of diagnostic modalities for thoracic malignancies
– be familiar with the most up to date form of treatment according to stage
– be able to choose and offer the patient several therapeutic modalities with an explanation of advantages and disadvantages
– be confident in drawing a treatment plan involving several specialists and treatment modalities (surgery, oncology and radiotherapy).
November 6, 2020
8:30
8:458:45
9:00Introduction
I° SESSION
How do we diagnose lung cancer?
CHAIR: A.Brunelli, M.Torre
9:00
9:20Nelson study: what have we learnt and what is left to do?
T. D’amico
9:20
9:40Alternatives to CT screening: are they viable?
G.Massard
9:40
10:00New bronchoscopic techniques: friend or foe?
N. Navani
10:00
10:20Radiologic diagnosis of lung cancer: when is it enough?
A. Patterson
10:20
10:40Intraoperative radiologic biopsy: does the cost justify the result?
K.Papagiannopoulos
10:40
11:00Questions
11:00
11:30Coffee Break
II° SESSION
How to approach lung cancer
Chair: G.Cardillo, K.Papagiannopoulos
11:30
11:50GGOs and subsolid lesions: classification and natural history
N. Novoa
11:50
12:10Resection vs surveillance for GGOs
N. Navani
12:10
12:30Surgery vs SBRT for operable patients: is there a role?
S. Arcangeli
12:30
12:50Surgery vs SBRT for operable patients: is there a role?
S. Arcangeli
12:50
13:10Surgery vs ENB navigation ablation
K. Lau
13:10
13:30Question
13:30
14:30Lunch
III° SESSION
Preoperative management
Chair: T.D’Amico, P.Solli
14:30
14:50Do we need to stage the mediastinum?
E. Ruffini
14:50
15:10Do we need to biopsy a lesion before surgery?
M. Ismail
15:10
15:30Neoadjuvant treatments for early stage lung cancer: is there a role?
D. Cortinovis
15:30
15:50Where do we draw the line for indications for surgery? The truly inoperable patient
A. Brunelli
15:50
16:10Question
16:10
16:40Coffee Break
IV° SESSION
How to treat early stage lung cancer
Chair: R.Crisci, G.Massard
16:40
17:00Robotic surgery
D. G. Rivas
17:00
17:20Minimally invasive approacches
D. G. Rivas
17:20
17:40Hybrid techniques
P. M. Falcoz
17:40
18:00How much can we push minimally invasive surgery?
H. Batirel
18:10
18:20Question and Closing Remarks
18:20
End of Day 1
November 7, 2020
8:00
8:30Registration
V° SESSION
Medical treatments
Chair: S.Arcangeli, N.Navani, J.Remon
8:30
8:50Immunotherapy in resectable NSCLC
Y. Summers
8:50
9:10News in immunotherapy world in advanced NSCLC: improving the bar
N. Peled
9:10
9:30Neoadjuvant strategies in oncogene addicted tumors: is it now the time?
I. Gil-Bazo
9:30
9:50Oncogene addicted tumors: new OMA’s to know
C. Rolfo
9:50
10:10SCLC a new dawn or the same old refrain
D. Cortinovis
10:10
10:30Questions
10:30
11:00Coffee Break
VI° SESSION
Multimodality treatments
Chair: M.Nosotti, A.Patterson
11:00
11:30Concomitant neoadjuvant chemoRT vs neoadjuvant chemo vs surgery upfront
T. D’amico
11:30
12:00Treatment of (un)resectable stage III lung cancer
F. Cappuzzo
12:00
12:30Oligometastatic disease: when is too much for surgery?
G. Rocco
12:30
13:00Multimodality approach for orphan diseases: MPM and SCLC
J. Remon
13:00
13:30CME Tests
13:30
Symposium End
13:30
14:30Lunch
INFO
International Thoracic Oncology Symposium| Fondazione Stelline | Palazzo delle Stelline, Corso Magenta 61 – 20123 Milano
| Email: info@thoraciconcology.it
ENDORSED BY
DISCLAIMER
The information contained in this website is for general information purposes only. The information is provided by International Thoracic Oncology Symposium and while we endeavour to keep the information up to date and correct, we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, reliability, suitability or availability with respect to the website or the information, products, services, or related graphics contained on the website for any purpose. Any reliance you place on such information is therefore strictly at your own risk.
© 2020 International Thoracic Oncology Symposium 2020 – Dev by Dep42